A statement of changes in beneficial ownership was filed on September 11, 2026, disclosing that Shiraz Shabanali Ladiwala, a director of Mesa Laboratories Inc /CO/, was awarded 2,510 Restricted Stock Units on September 9, 2026.

Key Highlights

  • Reporting person: Shiraz Shabanali Ladiwala, identified as a Director of Mesa Laboratories Inc /CO/
  • Security awarded: 2,510 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the issuer's common stock
  • Transaction date: September 9, 2026, with the filing submitted September 11, 2026
  • Price: RSUs were acquired at $0, with a vesting date of September 9, 2027
  • Resulting ownership: 2,510 derivative securities beneficially owned directly following the reported transaction
  • Issuer ticker: Mesa Laboratories trades under NASDAQ:MLAB

Director RSU Grant Details for Mesa Laboratories

According to the filing, Shiraz Shabanali Ladiwala, serving in the capacity of Director at Mesa Laboratories Inc /CO/ (NASDAQ:MLAB), received a grant of 2,510 Restricted Stock Units on September 9, 2026. The filing notes that each RSU represents a contingent right to receive one share of the issuer's common stock, and the units were acquired at a price of $0. The transaction was classified under Table II as a derivative security acquisition with transaction code "A," indicating an acquisition.

Mesa Laboratories is a Colorado-incorporated company listed on the NASDAQ exchange. The filing discloses that the awarded RSUs are scheduled to vest on September 9, 2027, one year from the transaction date. Following this grant, Ladiwala's direct beneficial ownership of these derivative securities stands at 2,510 units, all held directly. The filing was signed by John Sakys under Power of Attorney on behalf of Shiraz Ladiwala, and was submitted as a filing by one reporting person.

No shares of non-derivative common stock were reported as acquired, disposed of, or beneficially owned in Table I of the filing. The RSU award carries no exercise price, and the expiration date field was noted as "Not Applicable" in the filing's explanation of responses.

What Was Disclosed

The filing disclosed a grant of 2,510 RSUs to Mesa Laboratories director Shiraz Shabanali Ladiwala on September 9, 2026, at a price of $0, with vesting set for September 9, 2027, resulting in direct beneficial ownership of 2,510 derivative securities.